Daratumumab (Anti-CD38) interference with serological testing: An emerging challenge for blood banks in developing countries

Daratumumab (DARA), a monoclonal anti-CD38 antibody, belongs to the new generation of immunotherapy in refractory relapsed multiple myeloma. CD38 is weakly expressed on human erythrocytes. By its intrinsic anti-CD38 activity, DARA also interferes in routine pretransfusion compatibility testing such...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Rasika Setia, Mitu Dogra, Prerna Sachdeva, Anil Handoo, Dharma Choudhary, Amit Agarwal
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wolters Kluwer Medknow Publications 2017-01-01
סדרה:	Global Journal of Transfusion Medicine
נושאים:	Anti-CD38 antibody screening compatibility testing daratumumab dithiothreitol red blood cells serological interference
גישה מקוונת:	http://www.gjtmonline.com/article.asp?issn=2468-8398;year=2017;volume=2;issue=2;spage=163;epage=165;aulast=Setia
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!